What are the side effects of OjeMDA (tovorafenib)?

OjeMDA (tovorafenib) is a commonly used anticancer drug indicated for the treatment of children 6 months and older with relapsed or refractory low-grade glioma (LGG) with BRAF fusions or rearrangements or BRAF V600 mutations. However, it can also cause some side effects and adverse reactions.

Common adverse reactions include rash, hair color changes, fatigue, viral infection, vomiting, headache, bleeding, fever, dry skin, constipation, nausea, acneiform dermatitis, and upper respiratory tract infection. These adverse reactions may often occur during the use of OjeMDA, which will have a certain impact on the patient's quality of life. Therefore, during use, patients need to pay close attention to these reactions and report them to their doctor.

In addition, useOjeMDA may cause abnormal results in some laboratory tests. Common grade 3 or 4 laboratory abnormalities mainly include decreased phosphate, decreased hemoglobin, increased creatinine phosphokinase, increased alanine aminotransferase, decreased albumin, lymphopenia, leukopenia, increased aspartate aminotransferase, decreased potassium, and decreased sodium. These abnormalities may indicate changes in certain indicators in the patient's body while using OjeMDA, which requires timely monitoring and adjustment of the treatment plan.

Regarding Warnings and Precautions,Be aware of the risk of major bleeding events when using OjeMDA. This means that during treatment, patients may experience severe bleeding and require prompt medical attention. In addition, OjeMDA may cause skin reactions, including photosensitivity. This means patients may be more susceptible to skin damage or allergic reactions when exposed to the sun. In addition, OjeMDA may also have toxic effects on the liver, which may lead to abnormal liver function. In addition, OjeMDA has been associated with reduced growth rate, embryo-fetal toxicity, and neurofibromatosis type 1-related tumors.